▲ Peaking
Business
FDA approves Replimune melanoma drug previously rejected twice
The US Food and Drug Administration has approved Replimune's skin cancer drug following two earlier rejections.
Nivolumab
1 trends tracked about this subject — the full history, oldest to newest below.